Raymond James & Associates’s PLx Pharma Inc. Common Stock PLXP Stock Holding History

Raymond James & Associates’s Portfolio PLXP Stock Details PLXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-66,558	Closed	-$533K	–	4323
2021 Q4	$533K	Sell	66,558 -30,061	-31%	-$352K	﹤0.01%	3035
2021 Q3	$1.86M	Buy	96,619 +6,089	+7%	+$106K	﹤0.01%	2156
2021 Q2	$1.25M	Sell	90,530 -11,183	-11%	-$132K	﹤0.01%	2439
2021 Q1	$918K	Buy	+101,713	New	+$743K	﹤0.01%	2570
2018 Q3	–	Sell	-10,448	Closed	-$41K	–	3746
2018 Q2	$41K	Sell	10,448 -1,682	-14%	-$6.87K	﹤0.01%	3451
2018 Q1	$41K	Buy	12,130 +500	+4%	+$3.17K	﹤0.01%	3343
2017 Q4	$80K	Buy	+11,630	New	+$80.7K	﹤0.01%	3236
2016 Q4	–	Sell	-7,587	Closed	-$880K	–	3385
2016 Q3	$880K	Buy	7,587 +3,658	+93%	+$357K	﹤0.01%	1960
2016 Q2	$312K	Buy	+3,929	New	+$341K	﹤0.01%	2392

Other funds holding PLXP

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JMPWA

JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return

Raymond James & Associates's PLXP Position: Q1 2022 in Review

Raymond James & Associates sold out of PLx Pharma Inc. Common Stock (PLXP) in Q1 2022, closing a stake of 66,558 shares — an estimated $533K sold.

Raymond James & Associates first reported a position in PLXP in Q2 2016 and held it in 9 quarters. The position peaked at $1.86M in Q3 2021. 50 funds tracked by Wall St. Rank hold PLXP as of Q1 2022.

Raymond James & Associates reported no remaining PLx Pharma Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
Raymond James & Associates sold 66,558 PLx Pharma Inc. Common Stock shares in Q1 2022, an estimated $533K.
Raymond James & Associates first reported a position in PLx Pharma Inc. Common Stock in Q2 2016 and held it in 9 quarters.
Raymond James & Associates's PLx Pharma Inc. Common Stock position peaked at $1.86M in Q3 2021.
50 funds tracked by Wall St. Rank held PLx Pharma Inc. Common Stock as of Q1 2022.

Based on Raymond James & Associates's 13F filing for Q1 2022, filed 11 May 2022.